e-learning
resources
Munich 2006
Tuesday 05.09.2006
Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
P. Markart, M. Wygrecka, C. Ruppert, T. Koledachkina, W. Seeger, A. Guenther (Giessen, Germany)
Source:
Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Session:
Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Session type:
Oral Presentation
Number:
3335
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Markart, M. Wygrecka, C. Ruppert, T. Koledachkina, W. Seeger, A. Guenther (Giessen, Germany). Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection. Eur Respir J 2006; 28: Suppl. 50, 3335
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Histopathological assessment and classification
Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias
Year: 2006
Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia
Source: Eur Respir J 2003; 22: 239-244
Year: 2003
Changes of BAL findings as no progression marker in idiopathic pulmonary fibrosis (IPF) patients treated with IFN-g
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005
Histology and pathogenesis of usual interstitial pneumonia (UIP)
versus
nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Clinical categorisation of idiopathic interstitial pneumonia
Source: Annual Congress 2005 - Idiopathic pulmonary fibrosis: new concepts in its pathogenesis and management
Year: 2005
Cytokines, chemokines and growth factors concentration in BAL fluid from patients with Idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP)
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Interstitial fibrosis with a nodule
Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session
Year: 2007
KL-6/MUC1 in interstitial pneumonia
Source: Annual Congress 2005 - Lung-specific serum markers for interstitial lung diseases
Year: 2005
Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 409s
Year: 2001
Studies on interferon-gamma (IFN-γ) expression in lower airways of patients with idiopathic pulmonary fibrosis (IPF), sarcoidosis and pneumoconioses. Lower IFN-γ levels in bronchoalveolar lavage (BAL) supernatants of IPF subgroup with decrease
Source: Eur Respir J 2007; 30: Suppl. 51, 121s
Year: 2007
Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
Regulation of PMN apoptosis in the airways during community acquired pneumonia in COPD patients and controls
Source: Annual Congress 2006 - Molecular airway biology
Year: 2006
Elevated apoptosis rate of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonitis (NSIP) – strong positive correlation with bronchoalvoelar lavage (BAL) neutrophil count.
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept